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Introduction: Despite optimal surgery, some patients with early
endometrial carcinoma develop recurrence and die of disease. A number
of immunohistochemical (IHC)-identified cell products (markers) have
been proposed as predictors of recurrence. This study characterizes a large
series of endometrial carcinomas with previously described markers as
well as markers that have not been investigated in endometrial carcinoma.
Patients and methods: Women who had undergone surgery for endo-
metrial carcinoma were identified and specimens accessed. Tissue
blocks were evaluated for ten IHC markers. Results were correlated
with last known clinical status.
Results: Mean follow-up was 43 months; complete data were available
on 117 patients. Two women died of other causes; of the remaining 115,
eight died of disease and six were alive with recurrence at last follow-up
(12%). Vascular endothelial growth factor staining independently pre-
dicted recurrence and death. However, in multivariate analyses, only
FIGO stage predicted outcome.
Discussion: Our goal was to identify markers to predict which women
with endometrial carcinoma were likely to have disease recurrence. We
evaluated cell-cycle regulatory proteins, growth factors, hormone recep-
tors, and angiogenic factors, but did not identify any marker that inde-
pendently predicted outcome in multivariate analysis. This may reflect
the few negative outcomes in our population.
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Endometrial carcinoma is the most common gyneco-
logic malignancy affecting American women,
accounting for an estimated 39,300 new cases and
6600 deaths in the year 2002(1). Despite ‘definitive’
surgical therapy, many women with early stage endo-
metrial carcinoma go on to have recurrence and die of
disease. Known risk factors for progression include
specific histologic cell types, high histologic grade,
deep myometrial invasion, and presence of lymph-
vascular involvement. However, some women even
with apparent grade 1, stage I endometrioid type
tumors will experience recurrence. To date, there are
no known clinical or pathologic characteristics that
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identify which patients are at highest risk for recur-
rence and death.
The past decade has seen rapid advances in
research on and clinical application of immunohisto-
chemical (IHC) markers in a variety of malignant and
non-malignant diseases. Steroid hormones and their
receptors, oncogene products, and tumor suppressor
gene products have all been investigated as possible
predictors of tumor behavior as well as targets for
therapy. Characterization of estrogen and progester-
one receptor status in breast carcinomas is now stan-
dard care and serves to direct adjuvant therapies.
More recently, monoclonal antibodies against the
HER2/neu receptor in women with HER2/neu over-
expression have been included in standard adjuvant
therapy of breast cancer(2,3).
In the present study, we examine the prevalence of
ten IHC markers in endometrial carcinomas, and cor-
relate them with patient characteristics and outcome
data (Table 1). The markers can be broadly divided
into three general groups: (1) cell-cycle regulatory
proteins (tumor suppressor genes), (2) factors asso-
ciated with cell—cell adhesion and angiogenesis, and
(3) steroid hormone receptors. Each category of cellu-
lar product is thought to be dysregulated in solid
tumors: loss of expression of tumor suppressor
genes is a key permissive step in the uncontrolled
cell division of malignancy; neovascularization is cri-
tical to both local growth and metastasis of solid
tumors; and steroid hormones play key roles in reg-
ulating proliferation and differentiation of the endo-
metrium. Each of the markers studied could therefore
possibly predict more malignant behavior if its
expression is abnormal, and could also serve as a
future target for molecularly tailored therapy.
Previous studies have suggested that ER/PR nega-
tivity(4—6), overexpression of HER2/neu(7), vascular
endothelial growth factor (VEGF)(8—10), EGF-R(7,11),
p53(12—15), Ki-67(14), and TSP-1(16) may predict more
malignant behavior of endometrial carcinomas, as
reflected by advanced stage or grade, depth of inva-
sion, or lymphvascular space involvement. However,
clinical outcomes of patients have not been univer-
sally addressed in these investigations.
Additional studies have correlated overexpression of
HER2/neu with poorer outcomes in breast and ovarian
cancer(17—20). Investigations in breast carcinoma have
also associated clinical outcome with markers for
angiogenesis such as CD31(21), CD105(22,23), and
TSP-1(24). To our knowledge, CD31 and CD105 have
not previously been studied in endometrial carcinomas.
We hypothesize that the identification of new mar-
kers capable of predicting disease recurrence will
allow gynecologic oncologists to tailor both adjuvant
therapy and future surveillance for women with early
stage endometrial cancers.
Table 1. Immunohistochemical markers
Marker Class Function Role in tumorigenesis
p53 Tumor suppressor gene Arrests cell cycle for DNA Loss of wild-type allows uninhibited
repair, initiates apoptosis growth
Ki67 Nuclear protein Expressed in normal/neoplastic Reflects proliferative/mitotic activity
tissues throughout cell cycle
except G0
HER2/neu Oncogene product Membrane glycoprotein, partial Involved in cell-cell adhesion
homology to EGF-R Facilitates growth, invasion, and metastasis
EGF-R Oncogene product Promotes cell division, binds Overexpression promotes excessive growth
EGF and TGF-a Up-regulated by estrogen
VEGF Oncogene product Mitogen for vascular Promotes angiogenesis in normal
endothelial cells and neoplastic endometrium
CD31 Cell surface protein Regulates complex signaling Role in promoting angiogenesis
specific to vascular pathway; modulates cell adhesion reported in breast carcinomas
endothelium
CD105 Cell surface protein TGF-b receptor; modulates Binds TGF-b, required for angiogenesis;
specific to vascular TGF-b signaling role in angiogenesis reported in
endothelium breast carcinomas
TSP-1 Matrix-bound adhesive Regulates cell adhesion, May promote metastatic spread and
glycoprotein activates TGF-b angiogenesis
ER Steroid hormone Wide range of regulatory functions Uncertain; complex regulatory effect
receptor on many other pathways
PR Steroid hormone Wide range of regulatory functions Uncertain; complex regulatory effect on many
receptor other pathways
VEGF, vascular endothelial growth factor.
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Patients and methods
Approval of the investigation was obtained from the
Institutional Review Boards of all participating insti-
tutions. One hundred and forty-seven women with a
pathologic diagnosis of endometrial cancer were ret-
rospectively identified. All patients underwent surgi-
cal staging at the Hospital of the University of Rome
between 1996 and 2000. All slides were independently
re-reviewed by a single pathologist (PA) to verify the
diagnosis, histologic subtype, and grade. No signifi-
cant discrepancies were noted between the original
pathologic diagnoses and the diagnoses at review.
Clinical data collected included age at diagnosis, exis-
tence of common co-morbidities, use of exogenous
sex steroids, surgical stage of disease, results of patho-
logic evaluation, adjuvant therapy received, recur-
rence and interval to such, and last known status/
interval to death.
Immunohistochemistry
IHC staining was performed by Oncotech Inc. (Tustin,
CA) on fixed, paraffin-embedded tissue blocks. Sec-
tions 3—4 mm thick were deparaffinized in Histoclear,
and rehydrated in descending grades (100—70%) of
ethanol. Antigen retrieval included proteinase K or
protease digestion for CD31, CD105, VEGF, and
EGF-R, and microwaving for 20 min at 5 min intervals
for the p53, PR, HER2/neu, and Ki67 procedures.
Slides were kept in a pressure cooker for 20 min to
retrieve ER antigen. No antigen retrieval was neces-
sary for TSP-1 detection. Automated IHC procedures
were performed using I6000 (BioGenex, San Ramon,
CA) and NexES (Ventana, Phoenix, AZ) immunostai-
ners (Table 2). Endogenous peroxidase activity was
blocked by a 10-min treatment with 3% hydrogen
peroxide in distilled water. To minimize background
staining, sections were preincubated with normal goat
serum (BioGenex) for monoclonal antibodies. Slides
were incubated with primary antibodies for 30 min to
1 h. Immunoperoxide staining was accomplished
using the super sensitive streptavidin—biotin detec-
tion kit (BioGenex) or universal avidin—biotin Ventana
DAB detection system (Ventana, Phoenix, AZ). Coun-
terstain was then performed using hematoxylin or
methyl green prior to coverslipping and viewing by
light microscopy.
All slides were reviewed by a single histopatholo-
gist who was blinded to clinical outcomes (AK). For
ER, PR, VEGF, EGF-R, HER2/neu, and p53, slides
were assessed for the percentage of tumor cells posi-
tive for each stain as well as a subjective assessment of
intensity of staining, graded from 0 to 3þ. An IHC
score was then calculated for each slide by multiply-
ing the percentage of cells stained by a factor corre-
sponding to the intensity score (2 for 1þ staining, 3 for
2þ staining, and 4 for 3þ staining). For CD31 and
CD105, microvessel counts were performed at 200
magnification within designated ‘hotspots’ (areas
containing the greatest microvessel density), and
counted over at least three high-powered fields per
slide. The highest count from each specimen was
reported. For Ki-67, percentage of cells stained was
reported. Quantification of TSP-1 expression was per-
formed using a computer-assisted image analysis
(CAS 2000 two-color system; Becton Dickinson, San
Jose, CA). Analysis was carried out by measuring the
optical density of tumor specimens at 400 magnifi-
cation; multiple fields were examined within each
specimen and values were averaged.
Statistics
Clinical status at last follow-up was initially exam-
ined as an ordered discrete variable: alive without
disease, alive with recurrence, or dead of disease.
Two patients who died of other causes were excluded
Table 2. Immunohistochemical (IHC) antibodies
Antibody Manufacturer Clone IHC stainer Dilution Antigen retrieval AB incubation time (min)
ER NovoCastra (Newcastle upon Tyne, UK) 6F11 NexES 1 : 15 MW 32
PR BioGenex, San Ramon, CA PR88 I6000 1 : 80 MW 60
P53 Santa Cruz (Santa Cruz, CA) DO-1 NexES 1 : 200 MW 32
HER2/neu NeoMarkers (Fremont, CA) E2-4001 NexES 1 : 150 MW 32
EGF-R NeoMarkers (Fremont, CA) 111.6 NexES 1 : 400 Protease 8 min 32
VEGF Santa Cruz C-1 NexES 1 : 40 Protease 12 min 32
Ki67 Immunotech (Westbrook, ME) MIB-1 I6000 1 : 200 MW 60
CD31 DAKO (Carpinteria, CA) JC/70A NexES 1 : 40 Protease 12 min 32
CD105 DAKO (Carpinteria, CA) SN6h I6000 1 : 50 Proteinase K 60
TSP-1 Immunotech BG I6000 1 : 20 NA 60
VEGF, vascular endothelial growth factor.
Immunohistochemistry and endometrial cancer 147
# 2004 IGCS, International Journal of Gynecological Cancer 14, 145—151
from this analysis. Ordered probit models were spe-
cified and estimated by maximum likelihood using
the Stata (Stata Labs, San Mateo, CA) statistical pack-
age. First, a univariate analysis was performed of the
association of each IHC marker and clinical outcome.
Prior to performing multivariate analyses that included
the IHC markers, a multivariate ordered probit model
was specified that included age, stage, grade, and tumor
type. Grade and type had no statistically significant
predictive power for clinical status, and were excluded
from subsequent models. A multivariate ordered probit
analysis was then performed including age at diagnosis,
FIGO stage of disease, as well as each IHC marker in
turn. These analyses were performed first for the entire
study group, and then separately for only those women
with stage I disease (n¼ 95).
The data were also evaluated in a hazard frame-
work, using both a Cox proportional hazards model
and a discrete choice probit hazard model, to deter-
mine if the IHC markers were predictive of length of
time to the stated clinical outcomes (recurrence or
death). In these models, age and stage of disease
were controlled for. For the purposes of this analysis,
the two women who died of other causes were
included. These analyses were also performed with
the Stata1 statistical package.
Results
Complete follow-up data were available on 121
patients; the other 26 patients had incomplete docu-
mentation of disease status or were lost to follow-up.
Four patients had inadequate tumor volume for IHC
studies; thus there were 117 patients in the study
population. The mean age at diagnosis was 62.8
(range: 27—92). Only eight women (6.6%) were receiv-
ing exogenous hormones at the time of diagnosis.
Median duration of follow-up was 43 months from
the time of surgery (range 5—64; mean 41.2 13.4). At
the time of last contact, 101 were alive with no evi-
dence of disease, six were alive with known recur-
rence, eight were dead of disease, and two were dead
of other causes. Of the 14 women who had recurrent
disease or died of their malignancies, five had an
initial diagnosis of FIGO stage I cancer, one had stage
II, seven had stage III, and one had stage IV disease.
One hundred and five tumors had endometrioid
histology; ten were serous, and two were mucinous.
The tumors were graded according to WHO stan-
dards; of the endometrioid and mucinous cancers, 57
were grade 1, three were grade 2, and 47 were grade
3. All patients were assigned FIGO stages based on
intraoperative and pathologic findings. Ninety-one
patients had stage I disease, ten had stage II, 15 had
stage III, and one had stage IV disease (Table 3).
The most frequent primary surgical procedure was
radical abdominal hysterectomy with pelvic lymph
node sampling (n¼ 51, 44%). Thirty-seven women
had simple hysterectomy and lymph node sampling
(32%). Thirteen women underwent vaginal hysterect-
omy and lymph node sampling (11%), and three
women underwent Schauta with lymph node sam-
pling (2.5%). An additional 13 women underwent
either simple abdominal or vaginal hysterectomy
without lymphadenectomy (11%). The vast majority
of women had a concomitant bilateral salpingo-
oophorectomy (98%).
Thirty-eight women (32%) received no adjuvant
therapy. Thirty-four women (29%) received post-
operative radiation therapy alone, 16 (14%) received
chemotherapy alone, and 29 (25%) were treated with
both radiation therapy and chemotherapy.
Statistical analysis of each of the ten IHC markers
using the univariate ordered probit model revealed a
significant association of increased VEGF staining
with recurrence and death in univariate analyses
(P¼ 0.017) (Fig. 1). For an increase in VEGF one stan-
dard deviation above the mean, the probability of
recurrence increased from 4 to 8%, and the probability
of death of disease increased from 5 to 15% (Table 4).
However, in multivariate analyses, only known predic-
tors of outcome (age and FIGO stage of disease) were
significantly associated with poorer prognosis. These
findings did not differ between the entire study group
and the subgroup with stage I disease.
Additionally, we evaluated a panel of markers,
combining p53, TSP1, CD31. This ‘angiogenesis
index’ was not significantly predictive of clinical out-
come in either univariate or multivariate analysis.
Survival analyses using the Cox proportional
hazards model and the discrete choice probit model










Stage I 91 (78%)
Stage II 10 (8.5%)
Stage III 15 (12.8%)
Stage IV 1 (0.9%)
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revealed a statistically significant association of
increased VEGF staining with likelihood of recurrence
or death (P¼ 0.026 and 0.011 in each model, respect-
ively.) For an increase in VEGF staining one standard
deviation above the mean, the probability of recur-
rence or death increased from 3.5% per year (the risk
of negative clinical outcome in the study population
per 12-month period) to 6.2% per year. A decrease in
VEGF staining one standard deviation below the
mean decreased the probability of negative clinical
outcomes to 0.8% per year. However, when multivari-
ate survival analyses were performed including age
and stage of disease, no IHC marker significantly
predicted negative clinical outcome.
Discussion
Numerous prior investigators have examined IHC
markers in endometrial carcinoma both as identifiers
of more aggressive disease and as potential targets for
adjuvant therapies(4,5,7—13,15,16). The failure of the
majority of these studies to demonstrate significant
prognostic value for IHC markers may, in part, reflect
the small numbers of patients included and the het-
erogeneity of their diseases. Most previous studies
have included women at all FIGO stages of disease.
Those studies which do limit their analyses to only
stage I disease have included unusual histologic types
such as serous and clear cell carcinomas. Endometrial
cancers of these cell types are known to have more
malignant behaviors. Some of the major strengths of
this study are the large sample size, the relative
homogeneity of the pathologic diagnoses, and the
ability to separately analyze outcomes for women
with stage I disease. Women with later stages of dis-
ease or more aggressive histology are known a priori
to have a high risk of progression and/or recurrence.
Our study addresses the clinically more meritorious
question of which women with early stage endomet-
rioid carcinoma are at highest risk to progress. This
has particular clinical relevance as 90% of all women
with endometrial carcinomas have endometrioid his-
tology.
The finding that increased cellular VEGF expres-
sion in univariate analyses was predictive of poor
clinical outcome is provocative. VEGF has been
shown to regulate endometrial angiogenesis through-
out the normal menstrual cycle, and is implicated in
angiogenesis of endometrial carcinoma(8,9). It has also
been shown, in one study, to correlate with unfavor-
able clinical outcomes in patients with endometrial
carcinoma(8). The lack of significance in our multi-
variate analyses may be a result of the relatively low
number of patients with negative clinical outcomes in
our patient cohort. It is possible that, with a larger
number of recurrences and/or deaths, this finding
would persist in multivariate analyses.
Statistical power, in fact, is the greatest weakness of
the current study. While the total number of patients
evaluated was large, relatively few experienced the
negative outcomes of interest, decreasing the statis-
tical power of the study to identify predictors of these
outcomes. This distribution of clinical outcomes is not
surprising; the majority of our study patients had
stage I disease, and 5-year survival for stage I
endometrial carcinoma is repeatedly reported as
being approximately 85%(4,25).
Another possible confounder in the present study is
that many of the IHC markers studied correlated with
known prognostic variables, such as stage or grade,
and with each other (eg, ER and PR.) This may affect
the study results in two ways. Firstly, those IHC
markers that correlated with other predictors of prog-
nosis or with other markers are not truly independent
Fig. 1. Strong (3þ) staining of malignant endometrial glands for
vascular endothelial growth factor.
Table 4. Predictive probability of vascular endothelial growth factor staining in univariate ordered probit analysis
Immunohistochemical score Alive Recurrent cancer Dead of disease
150 (mean 1 SD) 0.98 0.01 0.01
300 (mean) 0.91 0.04 0.05
450 (meanþ 1 SD) 0.77 0.08 0.15
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variables, and the use of an ordered probit analysis
may be misleading. Secondly, those patients with
higher grade or stage tumors are more likely to have
received adjuvant therapy, which might attenuate the
course of the disease, or prevent the ‘sought’ negative
clinical outcomes. Therefore, those markers that cor-
related with advanced stage or grade may, in fact,
have a greater correlation with outcome than was
seen, because patients overexpressing these markers
received different therapy that positively affected the
course of their disease (prevented negative outcomes).
While the present study did not clearly identify an
IHC marker capable of distinguishing ‘high-risk’
early endometrial carcinoma, we are continuing to
search for a molecular marker(s) that better serve
this purpose. Meaningful and adequately powered
IHC evaluation of large numbers of early stage endo-
metrial cancers might be advanced by the use of
tumor banking and by cooperative investigations
among multiple institutions. Ultimately, we believe
that molecular profiling of individual patients’
tumors, to better prognosticate and to tailor therapy,
may allow for more specific and less toxic therapies.
Acknowledgments
This work was supported by an unrestricted educa-
tional grant from Oncotech, Inc. This study was pre-
sented at the annual meeting of the Western
Association of Gynecologic Oncologists, June 15,
2002, Newport Beach, CA.
References
1 American Cancer Society. Cancer Facts and Figures 2002,
Atlanta GA: American Cancer Society; 2002.
2 Burris H. Docetaxel (taxotere) plus trastuzumab (Hercep-
tin) in breast cancer. Semin Oncol 2001;28 (s3):38—44.
3 Hortobagyi GN. Overview of treatment results with
trastuzumab (Herceptin) in metastatic breast cancer.
Semin Oncol 2001;28 (6 S18):43—7.
4 Gehrig PA, Van Le L, Olatidoye B, Geradts J. Estrogen
receptor status, determined by immunohistochemistry,
as a predictor of the recurrence of stage I endometrial
carcinoma. Cancer 1999;86:2083—9.
5 Sivridis E, Giatromanolaki A, Koukourakis M,
Anastasiadis P. Endometrial carcinoma: association of
steroid hormone receptor expression with low angiogen-
esis and bcl-2 expression. Virchow’s Arch 2001;438:470—7.
6 Deligdisch L, Kase N, Bleiweiss I. Endometrial cancer in
elderly women: a histologic and steroid receptor analy-
sis. Gerontology 2000;46:17—21.
7 Khalifa M, Mannel R, Haraway S, Walker J, Min K.
Expression of EGF-R, HER-2/neu, P53, and PCNA in
endometrioid, serous papillary, and clear cell endome-
trial adenocarcinomas. Gynecol Oncol 1994;53:84—92.
8 Hirai M, Nakagawara A, Oosaki T, Hayashi Y, Horon M,
Yoshihara T. Expression of vascular endothelial growth
factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in
postmenopausal uterine endometrial carcinoma. Gynecol
Oncol 2001;80:181—8.
9 Seki N, Kodama J, Hongo A, Miyagi Y, Yoshinouchi M,
Kudo T. Vascular endothelial growth factor and platelet-
derived endothelial growth factor expression are impli-
cated in the angiogenesis of endometrial cancer. Eur J
Cancer 2000;36:68—73.
10 Fine BA, Valente PT, Feinstein GI, Dey T. VEGF, flt-1, and
KDR/flk-1 as prognostic indicator in endometrial carci-
noma. Gyn Oncol 2000;76:33—9.
11 Miturski R, Semczuk A, Postawski K, Jakowicki J.
Epidermal growth factor receptor immunostaining and
epidermal growth factor receptor-tyrosine kinase activity
in proliferative and neoplastic human endometrium.
Tumor Biol 2000;21:358—66.
12 Giatromanolaki A, Sivridis E, Koukourakis M, Harris A,
Gatter K. Bcl-2 and p53 expression in stage I endometrial
carcinoma. Anticancer Res 1998;18:3689—94.
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